Shots:
- The US FDA has approved Tukysa + trastuzumab & pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction treatment
- Approval was supported by the P-III (HER2CLIMB-05) trial data assessing Tukysa (n=326) vs PBO (n=328), both in combination with trastuzumab & pertuzumab, as a maintenance therapy for pts with HER2+ MBC following induction therapy
- In the P-III trial, Tukysa + trastuzumab & pertuzumab showed a 35.9% reduction in the risk of disease progression or death vs PBO, while the investigator-assessed mPFS was 24.9 vs 16.3mos.; data were published in The JCO
Ref: Businesswire | Image: Pfizer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
